Literature DB >> 3024084

Central nervous system metastases in epithelial ovarian carcinoma.

D M Larson, L J Copeland, R P Moser, J M Malone, D M Gershenson, J T Wharton.   

Abstract

With the advent of systemic chemotherapy capable of controlling metastases at most sites, central nervous system metastases are becoming more common in patients with epithelial ovarian carcinoma. A retrospective epidemiologic review at The University of Texas M. D. Anderson Hospital and Tumor Institute revealed central nervous system metastases in 13 of 4456 patients with epithelial ovarian carcinoma (0.29%) registered between 1944 and 1984. No patients were identified as having central nervous system metastases before 1968. The median survival overall was 29 months; following the diagnosis of brain metastases it was five months. Five of eight patients treated for central nervous system metastases lived ten months or longer. Patients with isolated metastases to the central nervous system lived longer than patients with accompanying systemic metastases. Patients treated with surgical resection lived longer than those who did not undergo surgery. With surgical resection, postoperative irradiation, and systemic chemotherapy, significant symptomatic improvement and long-term remission are possible.

Entities:  

Mesh:

Year:  1986        PMID: 3024084

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  14 in total

1.  Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate.

Authors:  Yasushi Goto; Noriyuki Katsumata; Shunichi Nakai; Yuko Sasajima; Kan Yonemori; Tsutomu Kouno; Chikako Shimizu; Masashi Ando; Yasuhiro Fujiwara
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

2.  Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.

Authors:  L T Vlasveld; J H Beynen; W Boogerd; W W Ten Bokkel Huinink; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Solitary cerebral metastasis from ovarian carcinoma: report of 4 cases.

Authors:  M Salvati; L Cervoni
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  Brain metastasis from ovarian cancer: a systematic review.

Authors:  Shabnam Pakneshan; Damoun Safarpour; Fattaneh Tavassoli; Bahman Jabbari
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

Review 5.  Brain metastasis from ovarian cancer: case report and review of the literature.

Authors:  Xi-Quan Hu; Jaime Imitola; Ryan Y Kim; Ali Mahta; Santosh Kesari
Journal:  Med Oncol       Date:  2011-03-06       Impact factor: 3.064

6.  Solitary cerebral metastases from ovarian epithelial carcinoma: 11 cases.

Authors:  Giancarlo D'Andrea; Raffaelino Roperto; Lavinia Dinia; Emanuela Caroli; Maurizio Salvati; Luigi Ferrante
Journal:  Neurosurg Rev       Date:  2004-11-19       Impact factor: 3.042

7.  Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome.

Authors:  Zvi R Cohen; Dima Suki; Jeffrey S Weinberg; Eric Marmor; Frederick F Lang; David M Gershenson; Raymond Sawaya
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

8.  Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain.

Authors:  Laura M Divine; Nora T Kizer; Andrea R Hagemann; Meredith E Pittman; Ling Chen; Matthew A Powell; David G Mutch; Janet S Rader; Premal H Thaker
Journal:  Gynecol Oncol       Date:  2016-05-08       Impact factor: 5.482

9.  Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

Authors:  A N van den Pol; X Zhang; E Lima; M Pitruzzello; N Albayrak; A Alvero; J N Davis; G Mor
Journal:  Virology       Date:  2020-11-12       Impact factor: 3.616

10.  Brain metastases from ovarian carcinoma.

Authors:  Ettie Piura; Benjamin Piura
Journal:  ISRN Oncol       Date:  2011-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.